Vanda Pharmaceuticals Company Profile (NASDAQ:VNDA)

About Vanda Pharmaceuticals

Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company's product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VNDA
  • CUSIP: 92165910
Key Metrics:
  • Previous Close: $14.17
  • 50 Day Moving Average: $12.00
  • 200 Day Moving Average: $9.86
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -47.69
  • P/E Growth: -1.95
  • Market Cap: $663.54M
  • Outstanding Shares: 43,284,000
  • Beta: 1.66
Additional Links:
Companies Related to Vanda Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Vanda Pharmaceuticals (NASDAQ:VNDA) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.00 (24.51% upside)

Analysts' Ratings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Show:
DateFirmActionRatingPrice TargetDetails
8/29/2016Brean CapitalReiterated RatingBuy$20.00 -> $24.00View Rating Details
8/26/2016JMP SecuritiesBoost Price TargetMarket Outperform$18.00 -> $22.00View Rating Details
8/18/2016Piper Jaffray Cos.Set Price TargetBuy$16.00View Rating Details
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details
3/14/2016Canaccord GenuityReiterated RatingBuy$18.00View Rating Details
(Data available from 8/29/2014 forward)

Earnings

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016        
7/27/2016Q216($0.23)($0.11)$36.03 million$36.02 millionViewListenView Earnings Details
5/4/2016Q116($0.24)($0.17)$32.48 million$33.30 millionViewListenView Earnings Details
2/10/2016Q415($0.26)($0.23)$31.34 million$31.85 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.11)$28.58 million$28.34 millionViewListenView Earnings Details
7/29/2015Q2($0.32)($0.01)$24.55 million$27.60 millionViewListenView Earnings Details
5/6/2015Q1($0.25)($0.24)$20.18 million$22.20 millionViewListenView Earnings Details
2/19/2015Q4$0.56($0.36)$35.57 million$15.40 millionViewListenView Earnings Details
10/27/2014Q314($0.39)($0.04)$12.20 million$14.80 millionViewListenView Earnings Details
8/7/2014Q2($0.70)($0.64)$10.00 million$10.80 millionViewListenView Earnings Details
5/8/2014Q1($0.29)($0.79)$8.50 million$9.10 millionViewListenView Earnings Details
2/13/2014Q413($0.20)($0.23)$8.50 million$8.80 millionViewListenView Earnings Details
11/7/2013Q313($0.30)($0.43)$8.45 million$8.70 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.22)($0.26)$8.43 million$8.30 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.25)($0.15)$8.42 million$8.10 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.22)($0.23)$8.60 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.22)($0.19)$8.40 million$8.28 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.28)ViewN/AView Earnings Details
5/8/2012($0.16)($0.28)ViewN/AView Earnings Details
2/14/2012($0.19)($0.20)ViewN/AView Earnings Details
11/4/2011($0.12)($0.11)ViewN/AView Earnings Details
8/4/2011($0.07)($0.05)ViewN/AView Earnings Details
2/10/2011($0.02)$0.08ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)
Current Year EPS Consensus Estimate: $-0.50 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.19)($0.19)($0.19)
Q4 20161($0.24)($0.24)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.44View SEC Filing  
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88View SEC Filing  
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.80View SEC Filing  
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32View SEC Filing  
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52View SEC Filing  
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20View SEC Filing  
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76View SEC Filing  
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60View SEC Filing  
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00View SEC Filing  
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vanda Pharmaceuticals (NASDAQ:VNDA)
DateHeadline
streetinsider.com logoVanda Pharmaceuticals (VNDA) Affirms Receipt of Favorable Court Decision in Fanapt Patent Suit (NASDAQ:VNDA)
www.streetinsider.com - August 27 at 7:10 PM
marketexclusive.com logoWhere Things Stand For Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) In Fanapt Patent Suit (NASDAQ:VNDA)
marketexclusive.com - August 27 at 7:10 PM
istreetwire.com logo3 Trending Stocks: Vanda Pharmaceuticals, Inc. (VNDA), The Gap, Inc. (GPS), Coeur Mining, Inc. (CDE) - iStreetWire (NASDAQ:VNDA)
istreetwire.com - August 26 at 7:43 PM
bizjournals.com logoVanda Pharmaceuticals fends off patent challenge from generic competitor (NASDAQ:VNDA)
www.bizjournals.com - August 26 at 7:43 PM
thestreet.com logoVanda Pharma (VNDA) Stock Price Target Upped on Drug Patent Ruling (NASDAQ:VNDA)
www.thestreet.com - August 26 at 7:43 PM
News IconNotable Trending Stocks: Vanda Pharmaceuticals Inc.(NASDAQ:VNDA), Dollar Tree, Inc. (NASDAQ:DLTR) - NYSE Journal (press release) (NASDAQ:VNDA)
stockznews.com - August 26 at 11:00 AM
News IconEyes Catching Healthcare Stocks- Nymox Pharmaceutical (NASDAQ:NYMX), Vanda Pharmaceuticals (NASDAQ:VNDA) - Seneca Globe (NASDAQ:VNDA)
www.senecaglobe.com - August 26 at 11:00 AM
finance.yahoo.com logoVanda Pharmaceuticals (VNDA) Catches Eye: Stocks Up 20% (NASDAQ:VNDA)
finance.yahoo.com - August 26 at 11:00 AM
finance.yahoo.com logoVanda Stock Up on Favorable U.S. Court Ruling for Fanapt (NASDAQ:VNDA)
finance.yahoo.com - August 26 at 11:00 AM
capitalcube.com logoETF’s with exposure to Vanda Pharmaceuticals, Inc. : August 26, 2016 (NASDAQ:VNDA)
www.capitalcube.com - August 26 at 11:00 AM
News IconVanda Patents Found Valid and Infringed in Fanapt® ANDA Litigation (NASDAQ:VNDA)
ih.advfn.com - August 25 at 8:25 PM
News IconVanda Pharmaceuticals Inc. (NASDAQ:VNDA): That’s How Our Subscribers bought at $11.90, Made 25% Quickly (NASDAQ:VNDA)
www.marketnewscall.com - August 25 at 8:25 PM
schaeffersresearch.com logoOptions Bulls Pounce as Vanda Pharmaceuticals Inc. (VNDA) Gaps Higher (NASDAQ:VNDA)
www.schaeffersresearch.com - August 25 at 8:24 PM
fool.com logoWhy Tiffany, AEP Industries, and Vanda Pharmaceuticals Jumped Today (NASDAQ:VNDA)
www.fool.com - August 25 at 7:22 PM
realistinvestor.com logoVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Reports Accounts Payable Of $17.933 - RealistInvestor.com (NASDAQ:VNDA)
www.realistinvestor.com - August 21 at 7:13 AM
capitalcube.com logoETF’s with exposure to Vanda Pharmaceuticals, Inc. : August 11, 2016 (NASDAQ:VNDA)
www.capitalcube.com - August 11 at 8:48 PM
4-traders.com logoGenocea Biosciences : Research Report Initiation on Biotech Stocks -- Agenus, ProNAi Therapeutics, Vanda Pharma, and Genocea Biosciences (NASDAQ:VNDA)
www.4-traders.com - August 11 at 11:37 AM
mysmartrend.com logoUptrend Call Working As Vanda Pharmaceuticals Stock Rises 19.6% (VNDA) (NASDAQ:VNDA)
www.mysmartrend.com - August 11 at 11:37 AM
nasdaq.com logoNoteworthy Wednesday Option Activity: VNDA, IP, PVH (NASDAQ:VNDA)
www.nasdaq.com - August 10 at 8:50 PM
capitalcube.com logoVanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:VNDA)
www.capitalcube.com - August 10 at 8:50 PM
streetupdates.com logoMost recent Analysts Rating report: Mednax, Inc (NYSE:MD) , Vanda ... - Street Updates (NASDAQ:VNDA)
www.streetupdates.com - August 8 at 8:21 PM
realistinvestor.com logoVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Quarterly Accounts Payable At $17.933 Millions - RealistInvestor.com (NASDAQ:VNDA)
www.realistinvestor.com - August 6 at 10:45 AM
finance.yahoo.com logoVANDA PHARMACEUTICALS INC. Financials (NASDAQ:VNDA)
finance.yahoo.com - August 3 at 8:32 PM
equities.com logoVanda Pharmaceuticals Inc. (VNDA) Jumps 6.58% on August 01 ... - Equities.com (NASDAQ:VNDA)
www.equities.com - August 2 at 7:23 AM
publicnow.com logoHETLIOZ® is Now Available for the Treatment of Non-24-Hour Sleep-Wake Disorder in Germany (NASDAQ:VNDA)
www.publicnow.com - August 1 at 7:21 AM
biz.yahoo.com logoVANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:VNDA)
biz.yahoo.com - August 1 at 7:11 AM
capitalcube.com logoETF’s with exposure to Vanda Pharmaceuticals, Inc. : July 29, 2016 (NASDAQ:VNDA)
www.capitalcube.com - July 29 at 2:01 PM
seekingalpha.com logoVanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:VNDA)
seekingalpha.com - July 28 at 8:37 PM
biz.yahoo.com logoVANDA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:VNDA)
biz.yahoo.com - July 28 at 7:04 AM
finance.yahoo.com logoEdited Transcript of VNDA earnings conference call or presentation 27-Jul-16 8:30pm GMT (NASDAQ:VNDA)
finance.yahoo.com - July 27 at 9:29 PM
4-traders.com logoVanda Pharmaceuticals : reports 2Q loss (NASDAQ:VNDA)
www.4-traders.com - July 27 at 8:37 PM
finance.yahoo.com logoVanda Pharmaceuticals Reports Second Quarter 2016 Financial Results (NASDAQ:VNDA)
finance.yahoo.com - July 27 at 8:37 PM
seekingalpha.com logoVanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2016 Results - Earnings Call Transcript (NASDAQ:VNDA)
seekingalpha.com - July 27 at 8:37 PM
sg.finance.yahoo.com logoVanda reports 2Q loss (NASDAQ:VNDA)
sg.finance.yahoo.com - July 27 at 5:45 PM
biz.yahoo.com logoQ2 2016 Vanda Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:VNDA)
biz.yahoo.com - July 27 at 7:07 AM
News IconVanda Pharmaceuticals Inc. (NASDAQ:VNDA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:VNDA)
www.engelwooddaily.com - July 22 at 7:59 PM
News IconEquity Roundup: Stock Performance Focus on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Press Telegraph (NASDAQ:VNDA)
presstelegraph.com - July 21 at 8:31 PM
News IconVanda Pharmaceuticals Incorporated (NASDAQ:VNDA) Shorted Shares Decreased By 3.15% - Consumer Eagle (NASDAQ:VNDA)
www.consumereagle.com - July 20 at 9:14 PM
News IconWere Analysts Bullish Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) This Week? - Press Telegraph (NASDAQ:VNDA)
presstelegraph.com - July 20 at 9:14 PM
News IconStock in Positive Territory for the Quarter: Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) - Engelwood Daily (NASDAQ:VNDA)
www.engelwooddaily.com - July 18 at 7:26 AM
fiscalstandard.com logoNext Weeks Broker Price Targets For Vanda Pharmaceuticals Inc. (VNDA) - Fiscal Standard (NASDAQ:VNDA)
www.fiscalstandard.com - July 17 at 7:32 PM
News IconShares Moving Down on the Week: Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) - Engelwood Daily (NASDAQ:VNDA)
www.engelwooddaily.com - July 16 at 7:26 PM
News IconVenbio Select Advisor LLC Decreased Stake in Vanda Pharmaceuticals INC (NASDAQ:VNDA) by $3.25 Million as ... - Consumer Eagle (NASDAQ:VNDA)
www.consumereagle.com - July 16 at 7:26 PM
News IconShares Experiencing a Downtrend: Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) - TGP (NASDAQ:VNDA)
telanaganapress.com - July 16 at 11:18 AM
realistinvestor.com logoVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Quarterly Accounts Payable At $22.664 Millions - RealistInvestor.com (NASDAQ:VNDA)
www.realistinvestor.com - July 16 at 11:18 AM
News IconTrading Performance and Target Watch for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Press Telegraph (NASDAQ:VNDA)
presstelegraph.com - July 15 at 7:08 PM
News IconVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:VNDA)
www.engelwooddaily.com - July 15 at 7:08 PM
News IconVanda Pharmaceuticals Incorporated (NASDAQ:VNDA) Short Interest Decreased By 3.15% - Consumer Eagle (NASDAQ:VNDA)
www.consumereagle.com - July 13 at 8:28 PM
news.cmlviz.com logoVanda Pharmaceuticals Inc Realized Volatility Hits Elevated Level - CML News (NASDAQ:VNDA)
news.cmlviz.com - July 13 at 8:28 PM
publicnow.com logoVanda Pharmaceuticals to Announce Second Quarter 2016 Financial Results on July 27, 2016 (NASDAQ:VNDA)
www.publicnow.com - July 12 at 4:43 PM

Social

Vanda Pharmaceuticals (NASDAQ:VNDA) Chart for Monday, August, 29, 2016


Last Updated on 8/29/2016 by MarketBeat.com Staff